Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Raised to $20.00

Iovance Biotherapeutics (NASDAQ:IOVA) had its price objective raised by HC Wainwright from $9.00 to $20.00 in a research report released on Tuesday morning, MarketBeat Ratings reports. The brokerage currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Iovance Biotherapeutics’ Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.10) EPS, FY2026 earnings at ($0.49) EPS and FY2027 earnings at ($0.24) EPS.

IOVA has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Thursday, July 2nd. Robert W. Baird set a $6.00 target price on shares of Iovance Biotherapeutics in a research note on Friday, August 7th. Mizuho raised their target price on Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “outperform” rating in a research report on Tuesday, August 18th. Barclays lifted their price target on Iovance Biotherapeutics from $13.00 to $15.00 and gave the company an “overweight” rating in a research note on Thursday, September 17th. Finally, The Goldman Sachs Group assumed coverage on Iovance Biotherapeutics in a report on Thursday, September 24th. They issued a “buy” rating and a $15.00 price target for the company. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $12.40.

Iovance Biotherapeutics Stock Down 4.0%

Iovance Biotherapeutics stock opened at $14.23 on Tuesday. The stock has a 50-day moving average price of $8.16 and a 200 day moving average price of $5.42. The company has a market capitalization of $6.45 billion, a price-to-earnings ratio of -19.49 and a beta of 0.75. Iovance Biotherapeutics has a 52 week low of $1.76 and a 52 week high of $15.30.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The company had revenue of $99.31 million for the quarter, compared to the consensus estimate of $87.83 million. During the same quarter in the prior year, the company earned ($0.33) EPS. Iovance Biotherapeutics’s quarterly revenue was up 65.7% on a year-over-year basis. Research analysts anticipate that Iovance Biotherapeutics will post -0.46 EPS for the current fiscal year.

Institutional Trading of Iovance Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in Iovance Biotherapeutics during the second quarter worth $153,744,000. Invenomic Capital Management LP raised its holdings in shares of Iovance Biotherapeutics by 13.5% during the 4th quarter. Invenomic Capital Management LP now owns 11,959,505 shares of the biotechnology company’s stock worth $32,649,000 after acquiring an additional 1,417,897 shares during the period. Palo Alto Investors LP purchased a new position in shares of Iovance Biotherapeutics during the 2nd quarter worth $22,032,229. Bank of America Corp DE acquired a new position in shares of Iovance Biotherapeutics during the 2nd quarter valued at about $20,773,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Iovance Biotherapeutics by 71.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,645,702 shares of the biotechnology company’s stock valued at $9,282,000 after acquiring an additional 1,106,592 shares during the last quarter. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Key Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance raised its 2026 revenue outlook to $410 million–$420 million, citing strong demand for its marketed therapies. The improved guidance fueled the recent surge and signals accelerating commercial adoption. IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $20 price target while raising its EPS estimates: 2026 losses to $0.49 per share from $0.58, 2027 losses to $0.24 from $0.35, and improving third- and fourth-quarter loss estimates. The revisions suggest better-than-expected operating performance. HC Wainwright Brokers Increase Earnings Estimates for IOVA
• Positive Sentiment: Wells Fargo raised its price target from $14 to $18 and assigned an Overweight rating. TD Cowen also initiated or reiterated a Buy rating, reinforcing favorable Wall Street sentiment. Iovance Receives a Buy from TD Cowen
• Neutral Sentiment: Iovance appointed Noah Berkowitz, M.D., Ph.D. as chief medical officer. His global drug-development experience in T-cell therapies could support clinical development and commercialization, although the appointment does not immediately change financial results. Iovance Appoints Noah Berkowitz as Chief Medical Officer
• Negative Sentiment: After gaining roughly 31% in the prior session, IOVA is experiencing some pullback and profit-taking. The stock’s elevated valuation and continuing expected losses leave it vulnerable to volatility if revenue growth or earnings improvements fall short of expectations. Iovance Shares Surge 31.5 Percent

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a biotechnology company focused on developing and commercializing individualized cell therapies for patients with cancer. The company’s platform uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded in a manufacturing facility and reinfused to help the immune system recognize and attack cancer cells.

Iovance’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved by the U.S. Food and Drug Administration for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment with a PD-1-blocking antibody and, when applicable, a BRAF-targeted therapy.